S
taphylococcus aureus is the most common cause of head and neck abscesses in children (1) (2) (3) (4) (5) (6) . It is a difficult organism to treat because it possesses the ability to adapt and develop resistance to multiple antibiotics. At Canadian pediatric otolaryngology tertiary referral centres, clindamycin is the antibiotic typically used to treat head and neck infections because most of the patients have already failed firstline therapy with penicillins. The aim of the present study was to retrospectively review trends in clindamycin resistance among S aureus head and neck abscesses between January 2000 and June 2008.
patients and Methods
A retrospective review of all S aureus bacterial cultures from a microbiology database at The Hospital for Sick Children (HSC) in Toronto, Ontario, between January 2000 and June 2008, was performed. The authors specifically identified all S aureus isolates from head and neck abscesses, and reviewed antimicrobial susceptibility patterns within this population. Patients younger than 18 years of age who presented with an abscess in the head and neck region, which was cultured and grew S aureus, were included in the study. Exclusion criteria included patients with intracranial lesions, a head and neck infection or a mass that did not culture S aureus, or a mass that was not classified as an abscess in the microbiology database.
The following information was gathered from the medical record of each of the identified patients: age, sex, date of diagnosis, type of abscess and antibiotics at time of specimen collection. The methicillinresistant S aureus (MRSA) strains were classified as hospital-acquired MRSA (HA-MRSA) or community-acquired MRSA (CA-MRSA) according to a standard epidemiological definition (7) .
The data were compared with overall trends of antimicrobial resistance in all S aureus isolates (inpatient and outpatient), regardless of body site (sterile and nonsterile sites), which were tested in the HSC laboratory over the same study period.
The research ethics board of the HSC granted approval for the present study.
Laboratory analysis
The antimicrobial susceptibility profile of each S aureus isolate (amoxicillin/clavulinic acid, ciprofloxacin, clindamycin, erythromycin, nitrofurantoin, gentamicin, levofloxacin, linezolid, oxacillin, penicillin, rifampin, trimethoprim-sulfamethoxazole [TMP-SMX], quinupristin/dalfopristin, tetracycline and vancomycin) was deter- 
ResuLts
In the data set that specifically reviewed S aureus head and neck abscesses, a total of 153 abscesses in 149 children were identified between January 2000 and June 2008. The median age was 15.1 months (range 0.5 to 208 months), and the male to female ratio was 1:1.33. Thirty-six per cent of patients were on clindamycin at the time of culture. Forty-three per cent of patients with clindamycin-resistant S aureus infections were being treated with clindamycin. 
Clindamycin susceptibility in head and neck abscesses

Methicillin resistance in head and neck abscesses
Over the study period, nine patients developed abscesses due to MRSA (Figure 2 ): one HA-MRSA case and eight CA-MRSA cases. Five of the CA-MRSA cases presented directly to the HSC and cultured MRSA within 48 h of presentation. Three of the CA-MRSA cases were transferred to the HSC after admission and failed antibiotic management at a local community hospital; incision and drainage revealed MRSA on culture. The HA-MRSA case was attributed to a hospital admission in another country. He subsequently presented to the HSC, with persistent MRSA sepsis. He developed a posterior triangle neck abscess from which MRSA was cultured. The HA-MRSA case, and three of the eight CA-MRSA cases, were resistant to clindamycin.
Methicillin resistance in all S aureus isolates
At the HSC, the number of new cases (all isolates) of MRSA per year increased from four cases in 2000 to 44 cases in 2007. In 2007, 34% of the MRSA cases were CA-MRSA, of which 18% showed clindamycin resistance. In contrast, 45% of HA-MRSA isolates were clindamycin resistant.
During the study period, only nine (6%) head and neck abscesses were MRSA positive. However, one-third of these MRSA-positive abscesses occurred within the final six months of the study period.
disCussion
In Canada, between 1995 and 2002, 49% of pediatric MRSA isolates (predominantly HA-MRSA) were resistant to clindamycin; however, CA-MRSA has been largely susceptible to clindamycin (7, 9) . This finding was corroborated in the United States by Ossowski et al (1) . In their analysis of 53 pediatric head and neck abscesses due to S aureus, they found that all MRSA isolates were susceptible to clindamycin. Therefore, they developed a treatment algorithm that recommended clindamycin as the initial empirical therapy (1) . It has been further recommended by the Committee on Infectious Diseases of the American Academy of Pediatrics that TMP-SMX be used for mild skin and soft tissue infections caused by CA-MRSA (10). However, there is concern regarding its efficacy against CA-MRSA and the paucity of clinical trials to characterize its effectiveness (1, 11, 12) . Furthermore, TMP-SMX is not effective against Streptococcus pyogenes and, therefore, should be used in conjunction with another agent to provide broader coverage.
A review of S aureus head and neck abscesses in the present study At the HSC, early incision and drainage is considered for all head and neck abscesses for diagnostic and therapeutic reasons. Alternatively, needle aspiration can be used to obtain a specimen for culture until definitive incision and drainage can be achieved. Clindamycin remains the initial broad-spectrum antibiotic of choice. Co-treatment with TMP-SMX is being considered; however, it is not presently the standard practice. As clindamycin resistance increases, TMP-SMX may prove to be a useful adjuvant given that the rate of TMP-SMX susceptibility at HSC is 88% for HA-MRSA and 91% for CA-MRSA. 
